The purpose of this study is to determine the safety and efficacy of MK-0431/ONO-5435 in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and glimepiride as...
Date First Received: August 11, 2006
Last Updated: February 27, 2009
Verified by: Ono Pharma, February 2009
Clinical Trial Phase: Phase 3 | Start Date: August 2006
Overall Status: Completed
Estimated Enrollment: 195
Brief Summary
Official Title: “MK-0431/ONO-5435 Phase III Clinical Study - Glimepiride Add-on Study for Patients With Type 2 Diabetes Mellitus”
Condition Keyword(s):
Intervention(s):
The purpose of this study is to determine the safety and efficacy of MK-0431/ONO-5435 in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and glimepiride as monotherapy
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Study Primary Completion Date: January 2008
Intervention(s) in this Clinical Trial
- Drug: Placebo
- Double-blind period (12 wk); placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
- Drug: Sitagliptin phosphate
- Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
Arms, Groups and Cohorts in this Clinical Trial
- Placebo Comparator: P
- Experimental: E
Outcome Measures for this Clinical Trial
Primary Measures
- HbA1c
- Time Frame: 12 weeks
Safety Issue?: No
- Time Frame: 12 weeks
- safety
- Time Frame: 52 weeks
Safety Issue?: Yes
- Time Frame: 52 weeks
- tolerability
- Time Frame: 52 weeks
Safety Issue?: Yes
- Time Frame: 52 weeks
Secondary Measures
- Plasma glucose
- Time Frame: 12 weeks
Safety Issue?: No
- Time Frame: 12 weeks
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Patients with Type 2 diabetes mellitus on diet/exercise therapy and glimepiride as monotherapy
Exclusion Criteria:
- Patients with Type 1 diabetes mellitus
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 20 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Ono Pharma
Overall Clinical Trial Officials and Contacts
Mikio Nishii Study Director Ono Pharma
Additional Information
Information obtained from ClinicalTrials.gov on July 02, 2009
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00363519
Study ID Number: ONO-5435-09
ClinicalTrials.gov Identifier: NCT00363519
Health Authority: Japan: Ministry of Health, Labor and Welfare
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.